Version history

{
  "content_md": "# Apelin Receptor Modulation Therapy\n\n## Overview\n\n\nflowchart TD\n    Apelin_Receptor_Modulation_The[\"Apelin Receptor Modulation Therapy\"]\n    Apelin_Receptor_Modulation_The[\"Therapy\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"table\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"class\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    style Apelin_Receptor_Modulation_The fill:#4fc3f7,stroke:#333,color:#000\n\n<table class=\"infobox infobox-therapeutic\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Apelin Receptor Modulation Therapy</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Peptide</td>\n    <td>Amino Acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-36</td>\n    <td>36</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-16</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-12</td>\n    <td>12</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Effect</td>\n    <td>Mechanism</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Amyloid Reduction</td>\n    <td>Enhanced autophagy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Tau Modification</td>\n    <td>GSK-3beta inhibition</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Synaptic Protection</td>\n    <td>CREB/BDNF</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Cognitive Improvement</td>\n    <td>Multiple</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Compound</td>\n    <td>Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">\\[Pyr^1\\]-Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule Agonists</td>\n    <td>Small molecule</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV-APJ</td>\n    <td>Gene therapy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Strategy</td>\n    <td>Approach</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Intranasal</td>\n    <td>Direct to CNS</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV Vector</td>\n    <td>Gene delivery</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Exosomes</td>\n    <td>Cell-derived</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule</td>\n    <td>Oral delivery</td>\n  </tr>\n</table>\n\nApelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[\"@obrien2012\"][@cook2014].\n\nApelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.\n\n## The Apelin-APJ System\n\n### Apelin Peptides\n\nThe apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:\n\nApelin-13 and its stable analog \\[Pyr^1\\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.\n\n### APJ Receptor (APLNR)\n\nThe APJ receptor is a Class A GPCR that:\n\n- Couples to multiple G proteins (Gαi/o, Gαq)\n- Activates PI3K/AKT, MAPK/ERK, and AMPK pathways\n- Undergoes ligand-dependent and independent (constitutive) signaling\n- Dimerizes with other receptors (e.g., angiotensin AT1 receptor)\n\n## Mechanisms of Neuroprotection\n\n### Autophagy Enhancement\n\nApelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:\n\n1. **AMPK Activation**: Phosphorylates AMPK, enhancing TFEB nuclear translocation\n2. **mTOR Inhibition**: Reduces mTORC1 activity, relieving autophagy suppression\n3. **Autophagosome Formation**: Increases LC3-II conversion and autophagosome numbers\n4. **Lysosomal Function**: Enhances lysosomal biogenesis and function\n\nThis autophagy enhancement is particularly relevant for:\n\n- **Alzheimer's Disease**: Clearing amyloid-beta and tau aggregates\n- **Parkinson's Disease**: Removing alpha-synuclein aggregates\n- **ALS**: Degrading TDP-43 and SOD1 aggregates\n\n### Blood-Brain Barrier Protection\n\nApelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:\n\n- **Tight Junction Preservation**: Maintains claudin-5 and ZO-1 expression\n- **Endothelial Survival**: Promotes endothelial cell survival via AKT\n- **Reduced Permeability**: Decreases BBB leakage in injury models\n- **Angiogenesis Regulation**: Modulates new vessel formation\n\nBBB protection is critical for:\n\n- Limiting neurotoxin entry into the CNS\n- Maintaining CNS immune privilege\n- Ensuring proper drug delivery\n\n### Neuroinflammation Modulation\n\nApelin modulates neuroinflammation through[@chen2024]:\n\n1. **Microglial Polarization**: Shifts microglia toward anti-inflammatory (M2) phenotype\n2. **Cytokine Reduction**: Decreases TNF-α, IL-1β, IL-6 production\n3. **NF-κB Inhibition**: Reduces pro-inflammatory signaling\n4. **T Cell Regulation**: Modulates CNS immune responses\n\n### Mitochondrial Protection\n\nApelin-13 promotes mitochondrial health:\n\n- **Biogenesis**: Increases PGC-1α expression and mitochondrial replication\n- **Fusion**: Enhances Mfn1/2 and OPA1-mediated fusion\n- **Mitophagy**: Facilitates PINK1/Parkin-independent mitophagy\n- **ATP Production**: Improves mitochondrial respiration\n\n### Neuronal Survival\n\nNeuroprotective signaling through:\n\n- **AKT Pathway**: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)\n- **ERK Pathway**: Activation promotes neuronal survival\n- **CREB Activation**: Enhances BDNF expression and synaptic plasticity\n- **Calcium Regulation**: Modulates calcium homeostasis\n\n## Role in Specific Diseases\n\n### Alzheimer's Disease\n\nApelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:\n\n### Parkinson's Disease\n\nApelin-13 shows neuroprotection in PD models[@yang2017]:\n\n- **Dopaminergic Protection**: Preserves tyrosine hydroxylase neurons\n- **Mitochondrial Rescue**: Improves complex I function\n- **Motor Improvement**: Reduces akinesia in MPTP models\n- **Alpha-Syn Clearance**: Autophagy enhancement\n\n### Amyotrophic Lateral Sclerosis\n\nIn ALS models, apelin shows[@jiang2018]:\n\n- **Motor Neuron Protection**: Reduces motor neuron loss\n- **Glial Modulation**: Affects astrocyte and microglial reactivity\n- **SOD1 Clearance**: Enhances mutant SOD1 removal\n- **Extended Survival**: Improves lifespan in transgenic models\n\n### CBS/PSP (4R-Tauopathies)\n\nApelin modulation may benefit 4R-tauopathies:\n\n- **Tau Clearance**: Autophagy enhancement aids tau removal\n- **BBB Protection**: Important for brainstem regions affected in PSP\n- **Neuroinflammation**: Reduces tau-induced inflammation\n\n## Therapeutic Approaches\n\n### Apelin Receptor Agonists\n\n### Apelin Peptide Analogs\n\nModified analogs under development:\n\n- **PEGylated apelin**: Extended half-life\n- **D-amino acid analogs**: Protease resistance\n- **Small peptide fragments**: Blood-brain barrier penetration\n\n### Clinical Trials\n\nCurrently limited clinical trial data for CNS applications:\n\n1. **(TBD)**: Apelin infusion in heart failure (not CNS)\n2. **(TBD)**: APJ agonist in pulmonary hypertension\n3. No registered trials for neurodegenerative indications\n\n### Challenges\n\n- **BBB Penetration**: Apelin peptides do not cross BBB efficiently\n- **Stability**: Rapid degradation by proteases\n- **Receptor Desensitization**: Chronic exposure reduces signaling\n- **Dose Timing**: Optimal window for intervention unclear\n\n### Delivery Strategies\n\n## Cross-References\n\n- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)\n- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)\n- [Corticobasal Syndrome](/diseases/corticobasal-degeneration)\n\n## See Also\n\n- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)\n- [Neuroprotective Strategies](/therapeutics/nfl-reduction-therapy)\n- [Peptide Therapeutics](/content/therapeutics)\n- [Gene Therapy Approaches](/therapeutics/section-113-emerging-gene-therapy-cbs-psp)\n- [Autophagy Modulators](/mechanisms/autophagy-lysosome-pathway)\n\n## External Links\n\n- [NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)\n- [UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)\n- [PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)\n\n## References\n\n1. [O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.\n\n2. [Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.\n\n3. [Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.\n\n4. [Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.\n\n5. [Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.\n\n6. [Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.\n\n7. [Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.\n\n8. [Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.\n\n9. [Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.\n\n10. [Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style=\"color:#ffd54f;font-weight:600\">0.44</span> · Target: TH, AADC\n- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style=\"color:#81c784;font-weight:600\">0.73</span> · Target: BDNF\n- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style=\"color:#81c784;font-weight:600\">0.71</span> · Target: GLP1R, BDNF\n- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style=\"color:#ffd54f;font-weight:600\">0.48</span> · Target: CHR2/BDNF\n- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: CYP46A1\n- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SST\n- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: HCRTR1/HCRTR2\n- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SMPD1\n\n\n**Related Analyses:**\n- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;\n- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;\n- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;\n",
  "entity_type": "therapeutic"
}

{
  "content_md": "# Apelin Receptor Modulation Therapy\n\n## Overview\n\n\n```mermaid\nflowchart TD\n    Apelin_Receptor_Modulation_The[\"Apelin Receptor Modulation Therapy\"]\n    Apelin_Receptor_Modulation_The[\"Therapy\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"table\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"class\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    style Apelin_Receptor_Modulation_The fill:#4fc3f7,stroke:#333,color:#000\n```\n\n<table class=\"infobox infobox-therapeutic\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Apelin Receptor Modulation Therapy</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Peptide</td>\n    <td>Amino Acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-36</td>\n    <td>36</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-16</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-12</td>\n    <td>12</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Effect</td>\n    <td>Mechanism</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Amyloid Reduction</td>\n    <td>Enhanced autophagy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Tau Modification</td>\n    <td>GSK-3beta inhibition</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Synaptic Protection</td>\n    <td>CREB/BDNF</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Cognitive Improvement</td>\n    <td>Multiple</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Compound</td>\n    <td>Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">\\[Pyr^1\\]-Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule Agonists</td>\n    <td>Small molecule</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV-APJ</td>\n    <td>Gene therapy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Strategy</td>\n    <td>Approach</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Intranasal</td>\n    <td>Direct to CNS</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV Vector</td>\n    <td>Gene delivery</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Exosomes</td>\n    <td>Cell-derived</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule</td>\n    <td>Oral delivery</td>\n  </tr>\n</table>\n\nApelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[\"@obrien2012\"][@cook2014].\n\nApelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.\n\n## The Apelin-APJ System\n\n### Apelin Peptides\n\nThe apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:\n\nApelin-13 and its stable analog \\[Pyr^1\\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.\n\n### APJ Receptor (APLNR)\n\nThe APJ receptor is a Class A GPCR that:\n\n- Couples to multiple G proteins (Gαi/o, Gαq)\n- Activates PI3K/AKT, MAPK/ERK, and AMPK pathways\n- Undergoes ligand-dependent and independent (constitutive) signaling\n- Dimerizes with other receptors (e.g., angiotensin AT1 receptor)\n\n## Mechanisms of Neuroprotection\n\n### Autophagy Enhancement\n\nApelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:\n\n1. **AMPK Activation**: Phosphorylates AMPK, enhancing TFEB nuclear translocation\n2. **mTOR Inhibition**: Reduces mTORC1 activity, relieving autophagy suppression\n3. **Autophagosome Formation**: Increases LC3-II conversion and autophagosome numbers\n4. **Lysosomal Function**: Enhances lysosomal biogenesis and function\n\nThis autophagy enhancement is particularly relevant for:\n\n- **Alzheimer's Disease**: Clearing amyloid-beta and tau aggregates\n- **Parkinson's Disease**: Removing alpha-synuclein aggregates\n- **ALS**: Degrading TDP-43 and SOD1 aggregates\n\n### Blood-Brain Barrier Protection\n\nApelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:\n\n- **Tight Junction Preservation**: Maintains claudin-5 and ZO-1 expression\n- **Endothelial Survival**: Promotes endothelial cell survival via AKT\n- **Reduced Permeability**: Decreases BBB leakage in injury models\n- **Angiogenesis Regulation**: Modulates new vessel formation\n\nBBB protection is critical for:\n\n- Limiting neurotoxin entry into the CNS\n- Maintaining CNS immune privilege\n- Ensuring proper drug delivery\n\n### Neuroinflammation Modulation\n\nApelin modulates neuroinflammation through[@chen2024]:\n\n1. **Microglial Polarization**: Shifts microglia toward anti-inflammatory (M2) phenotype\n2. **Cytokine Reduction**: Decreases TNF-α, IL-1β, IL-6 production\n3. **NF-κB Inhibition**: Reduces pro-inflammatory signaling\n4. **T Cell Regulation**: Modulates CNS immune responses\n\n### Mitochondrial Protection\n\nApelin-13 promotes mitochondrial health:\n\n- **Biogenesis**: Increases PGC-1α expression and mitochondrial replication\n- **Fusion**: Enhances Mfn1/2 and OPA1-mediated fusion\n- **Mitophagy**: Facilitates PINK1/Parkin-independent mitophagy\n- **ATP Production**: Improves mitochondrial respiration\n\n### Neuronal Survival\n\nNeuroprotective signaling through:\n\n- **AKT Pathway**: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)\n- **ERK Pathway**: Activation promotes neuronal survival\n- **CREB Activation**: Enhances BDNF expression and synaptic plasticity\n- **Calcium Regulation**: Modulates calcium homeostasis\n\n## Role in Specific Diseases\n\n### Alzheimer's Disease\n\nApelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:\n\n### Parkinson's Disease\n\nApelin-13 shows neuroprotection in PD models[@yang2017]:\n\n- **Dopaminergic Protection**: Preserves tyrosine hydroxylase neurons\n- **Mitochondrial Rescue**: Improves complex I function\n- **Motor Improvement**: Reduces akinesia in MPTP models\n- **Alpha-Syn Clearance**: Autophagy enhancement\n\n### Amyotrophic Lateral Sclerosis\n\nIn ALS models, apelin shows[@jiang2018]:\n\n- **Motor Neuron Protection**: Reduces motor neuron loss\n- **Glial Modulation**: Affects astrocyte and microglial reactivity\n- **SOD1 Clearance**: Enhances mutant SOD1 removal\n- **Extended Survival**: Improves lifespan in transgenic models\n\n### CBS/PSP (4R-Tauopathies)\n\nApelin modulation may benefit 4R-tauopathies:\n\n- **Tau Clearance**: Autophagy enhancement aids tau removal\n- **BBB Protection**: Important for brainstem regions affected in PSP\n- **Neuroinflammation**: Reduces tau-induced inflammation\n\n## Therapeutic Approaches\n\n### Apelin Receptor Agonists\n\n### Apelin Peptide Analogs\n\nModified analogs under development:\n\n- **PEGylated apelin**: Extended half-life\n- **D-amino acid analogs**: Protease resistance\n- **Small peptide fragments**: Blood-brain barrier penetration\n\n### Clinical Trials\n\nCurrently limited clinical trial data for CNS applications:\n\n1. **(TBD)**: Apelin infusion in heart failure (not CNS)\n2. **(TBD)**: APJ agonist in pulmonary hypertension\n3. No registered trials for neurodegenerative indications\n\n### Challenges\n\n- **BBB Penetration**: Apelin peptides do not cross BBB efficiently\n- **Stability**: Rapid degradation by proteases\n- **Receptor Desensitization**: Chronic exposure reduces signaling\n- **Dose Timing**: Optimal window for intervention unclear\n\n### Delivery Strategies\n\n## Cross-References\n\n- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)\n- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)\n- [Corticobasal Syndrome](/diseases/corticobasal-degeneration)\n\n## See Also\n\n- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)\n- [Neuroprotective Strategies](/therapeutics/nfl-reduction-therapy)\n- [Peptide Therapeutics](/content/therapeutics)\n- [Gene Therapy Approaches](/therapeutics/section-113-emerging-gene-therapy-cbs-psp)\n- [Autophagy Modulators](/mechanisms/autophagy-lysosome-pathway)\n\n## External Links\n\n- [NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)\n- [UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)\n- [PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)\n\n## References\n\n1. [O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.\n\n2. [Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.\n\n3. [Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.\n\n4. [Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.\n\n5. [Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.\n\n6. [Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.\n\n7. [Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.\n\n8. [Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.\n\n9. [Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.\n\n10. [Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style=\"color:#ffd54f;font-weight:600\">0.44</span> · Target: TH, AADC\n- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style=\"color:#81c784;font-weight:600\">0.73</span> · Target: BDNF\n- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style=\"color:#81c784;font-weight:600\">0.71</span> · Target: GLP1R, BDNF\n- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style=\"color:#ffd54f;font-weight:600\">0.48</span> · Target: CHR2/BDNF\n- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: CYP46A1\n- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SST\n- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: HCRTR1/HCRTR2\n- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SMPD1\n\n\n**Related Analyses:**\n- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;\n- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;\n- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;\n",
  "entity_type": "therapeutic"
}

{
  "content_md": "# Apelin Receptor Modulation Therapy\n\n## Overview\n\n\nflowchart TD\n    Apelin_Receptor_Modulation_The[\"Apelin Receptor Modulation Therapy\"]\n    Apelin_Receptor_Modulation_The[\"Therapy\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"table\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"class\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    style Apelin_Receptor_Modulation_The fill:#4fc3f7,stroke:#333,color:#000\n\n<table class=\"infobox infobox-therapeutic\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Apelin Receptor Modulation Therapy</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Peptide</td>\n    <td>Amino Acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-36</td>\n    <td>36</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-16</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-12</td>\n    <td>12</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Effect</td>\n    <td>Mechanism</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Amyloid Reduction</td>\n    <td>Enhanced autophagy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Tau Modification</td>\n    <td>GSK-3β inhibition</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Synaptic Protection</td>\n    <td>CREB/BDNF</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Cognitive Improvement</td>\n    <td>Multiple</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Compound</td>\n    <td>Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">\\[Pyr^1\\]-Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule Agonists</td>\n    <td>Small molecule</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV-APJ</td>\n    <td>Gene therapy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Strategy</td>\n    <td>Approach</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Intranasal</td>\n    <td>Direct to CNS</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV Vector</td>\n    <td>Gene delivery</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Exosomes</td>\n    <td>Cell-derived</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule</td>\n    <td>Oral delivery</td>\n  </tr>\n</table>\n\nApelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[@obrien2012][@cook2014].\n\nApelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.\n\n## The Apelin-APJ System\n\n### Apelin Peptides\n\nThe apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:\n\nApelin-13 and its stable analog \\[Pyr^1\\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.\n\n### APJ Receptor (APLNR)\n\nThe APJ receptor is a Class A GPCR that:\n\n- Couples to multiple G proteins (Gαi/o, Gαq)\n- Activates PI3K/AKT, MAPK/ERK, and AMPK pathways\n- Undergoes ligand-dependent and independent (constitutive) signaling\n- Dimerizes with other receptors (e.g., angiotensin AT1 receptor)\n\n## Mechanisms of Neuroprotection\n\n### Autophagy Enhancement\n\nApelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:\n\n1. **AMPK Activation**: Phosphorylates AMPK, enhancing TFEB nuclear translocation\n2. **mTOR Inhibition**: Reduces mTORC1 activity, relieving autophagy suppression\n3. **Autophagosome Formation**: Increases LC3-II conversion and autophagosome numbers\n4. **Lysosomal Function**: Enhances lysosomal biogenesis and function\n\nThis autophagy enhancement is particularly relevant for:\n\n- **Alzheimer's Disease**: Clearing amyloid-beta and tau aggregates\n- **Parkinson's Disease**: Removing alpha-synuclein aggregates\n- **ALS**: Degrading TDP-43 and SOD1 aggregates\n\n### Blood-Brain Barrier Protection\n\nApelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:\n\n- **Tight Junction Preservation**: Maintains claudin-5 and ZO-1 expression\n- **Endothelial Survival**: Promotes endothelial cell survival via AKT\n- **Reduced Permeability**: Decreases BBB leakage in injury models\n- **Angiogenesis Regulation**: Modulates new vessel formation\n\nBBB protection is critical for:\n\n- Limiting neurotoxin entry into the CNS\n- Maintaining CNS immune privilege\n- Ensuring proper drug delivery\n\n### Neuroinflammation Modulation\n\nApelin modulates neuroinflammation through[@chen2024]:\n\n1. **Microglial Polarization**: Shifts microglia toward anti-inflammatory (M2) phenotype\n2. **Cytokine Reduction**: Decreases TNF-α, IL-1β, IL-6 production\n3. **NF-κB Inhibition**: Reduces pro-inflammatory signaling\n4. **T Cell Regulation**: Modulates CNS immune responses\n\n### Mitochondrial Protection\n\nApelin-13 promotes mitochondrial health:\n\n- **Biogenesis**: Increases PGC-1α expression and mitochondrial replication\n- **Fusion**: Enhances Mfn1/2 and OPA1-mediated fusion\n- **Mitophagy**: Facilitates PINK1/Parkin-independent mitophagy\n- **ATP Production**: Improves mitochondrial respiration\n\n### Neuronal Survival\n\nNeuroprotective signaling through:\n\n- **AKT Pathway**: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)\n- **ERK Pathway**: Activation promotes neuronal survival\n- **CREB Activation**: Enhances BDNF expression and synaptic plasticity\n- **Calcium Regulation**: Modulates calcium homeostasis\n\n## Role in Specific Diseases\n\n### Alzheimer's Disease\n\nApelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:\n\n### Parkinson's Disease\n\nApelin-13 shows neuroprotection in PD models[@yang2017]:\n\n- **Dopaminergic Protection**: Preserves tyrosine hydroxylase neurons\n- **Mitochondrial Rescue**: Improves complex I function\n- **Motor Improvement**: Reduces akinesia in MPTP models\n- **Alpha-Syn Clearance**: Autophagy enhancement\n\n### Amyotrophic Lateral Sclerosis\n\nIn ALS models, apelin shows[@jiang2018]:\n\n- **Motor Neuron Protection**: Reduces motor neuron loss\n- **Glial Modulation**: Affects astrocyte and microglial reactivity\n- **SOD1 Clearance**: Enhances mutant SOD1 removal\n- **Extended Survival**: Improves lifespan in transgenic models\n\n### CBS/PSP (4R-Tauopathies)\n\nApelin modulation may benefit 4R-tauopathies:\n\n- **Tau Clearance**: Autophagy enhancement aids tau removal\n- **BBB Protection**: Important for brainstem regions affected in PSP\n- **Neuroinflammation**: Reduces tau-induced inflammation\n\n## Therapeutic Approaches\n\n### Apelin Receptor Agonists\n\n### Apelin Peptide Analogs\n\nModified analogs under development:\n\n- **PEGylated apelin**: Extended half-life\n- **D-amino acid analogs**: Protease resistance\n- **Small peptide fragments**: Blood-brain barrier penetration\n\n### Clinical Trials\n\nCurrently limited clinical trial data for CNS applications:\n\n1. **(TBD)**: Apelin infusion in heart failure (not CNS)\n2. **(TBD)**: APJ agonist in pulmonary hypertension\n3. No registered trials for neurodegenerative indications\n\n### Challenges\n\n- **BBB Penetration**: Apelin peptides do not cross BBB efficiently\n- **Stability**: Rapid degradation by proteases\n- **Receptor Desensitization**: Chronic exposure reduces signaling\n- **Dose Timing**: Optimal window for intervention unclear\n\n### Delivery Strategies\n\n## Cross-References\n\n- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)\n- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)\n- [Corticobasal Syndrome](/diseases/corticobasal-degeneration)\n\n## See Also\n\n- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)\n- [Neuroprotective Strategies](/therapeutics/nfl-reduction-therapy)\n- [Peptide Therapeutics](/content/therapeutics)\n- [Gene Therapy Approaches](/therapeutics/section-113-emerging-gene-therapy-cbs-psp)\n- [Autophagy Modulators](/mechanisms/autophagy-lysosome-pathway)\n\n## External Links\n\n- [NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)\n- [UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)\n- [PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)\n\n## References\n\n1. [O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.\n\n2. [Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.\n\n3. [Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.\n\n4. [Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.\n\n5. [Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.\n\n6. [Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.\n\n7. [Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.\n\n8. [Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.\n\n9. [Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.\n\n10. [Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style=\"color:#ffd54f;font-weight:600\">0.44</span> · Target: TH, AADC\n- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style=\"color:#81c784;font-weight:600\">0.73</span> · Target: BDNF\n- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style=\"color:#81c784;font-weight:600\">0.71</span> · Target: GLP1R, BDNF\n- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style=\"color:#ffd54f;font-weight:600\">0.48</span> · Target: CHR2/BDNF\n- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: CYP46A1\n- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SST\n- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: HCRTR1/HCRTR2\n- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SMPD1\n\n\n**Related Analyses:**\n- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;\n- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;\n- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;\n",
  "entity_type": "therapeutic"
}

{
  "content_md": "# Apelin Receptor Modulation Therapy\n\n## Overview\n\n\n```mermaid\nflowchart TD\n    Apelin_Receptor_Modulation_The[\"Apelin Receptor Modulation Therapy\"]\n    Apelin_Receptor_Modulation_The[\"Therapy\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"table\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    Apelin_Receptor_Modulation_The[\"class\"]\n    Apelin_Receptor_Modulation_The -->|\"related to\"| Apelin_Receptor_Modulation_The\n    style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000\n    style Apelin_Receptor_Modulation_The fill:#4fc3f7,stroke:#333,color:#000\n```\n\n<table class=\"infobox infobox-therapeutic\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Apelin Receptor Modulation Therapy</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Peptide</td>\n    <td>Amino Acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-36</td>\n    <td>36</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-16</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-12</td>\n    <td>12</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Effect</td>\n    <td>Mechanism</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Amyloid Reduction</td>\n    <td>Enhanced autophagy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Tau Modification</td>\n    <td>GSK-3β inhibition</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Synaptic Protection</td>\n    <td>CREB/BDNF</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Cognitive Improvement</td>\n    <td>Multiple</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Compound</td>\n    <td>Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">\\[Pyr^1\\]-Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule Agonists</td>\n    <td>Small molecule</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV-APJ</td>\n    <td>Gene therapy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Strategy</td>\n    <td>Approach</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Intranasal</td>\n    <td>Direct to CNS</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV Vector</td>\n    <td>Gene delivery</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Exosomes</td>\n    <td>Cell-derived</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule</td>\n    <td>Oral delivery</td>\n  </tr>\n</table>\n\nApelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[@obrien2012][@cook2014].\n\nApelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.\n\n## The Apelin-APJ System\n\n### Apelin Peptides\n\nThe apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:\n\nApelin-13 and its stable analog \\[Pyr^1\\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.\n\n### APJ Receptor (APLNR)\n\nThe APJ receptor is a Class A GPCR that:\n\n- Couples to multiple G proteins (Gαi/o, Gαq)\n- Activates PI3K/AKT, MAPK/ERK, and AMPK pathways\n- Undergoes ligand-dependent and independent (constitutive) signaling\n- Dimerizes with other receptors (e.g., angiotensin AT1 receptor)\n\n## Mechanisms of Neuroprotection\n\n### Autophagy Enhancement\n\nApelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:\n\n1. **AMPK Activation**: Phosphorylates AMPK, enhancing TFEB nuclear translocation\n2. **mTOR Inhibition**: Reduces mTORC1 activity, relieving autophagy suppression\n3. **Autophagosome Formation**: Increases LC3-II conversion and autophagosome numbers\n4. **Lysosomal Function**: Enhances lysosomal biogenesis and function\n\nThis autophagy enhancement is particularly relevant for:\n\n- **Alzheimer's Disease**: Clearing amyloid-beta and tau aggregates\n- **Parkinson's Disease**: Removing alpha-synuclein aggregates\n- **ALS**: Degrading TDP-43 and SOD1 aggregates\n\n### Blood-Brain Barrier Protection\n\nApelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:\n\n- **Tight Junction Preservation**: Maintains claudin-5 and ZO-1 expression\n- **Endothelial Survival**: Promotes endothelial cell survival via AKT\n- **Reduced Permeability**: Decreases BBB leakage in injury models\n- **Angiogenesis Regulation**: Modulates new vessel formation\n\nBBB protection is critical for:\n\n- Limiting neurotoxin entry into the CNS\n- Maintaining CNS immune privilege\n- Ensuring proper drug delivery\n\n### Neuroinflammation Modulation\n\nApelin modulates neuroinflammation through[@chen2024]:\n\n1. **Microglial Polarization**: Shifts microglia toward anti-inflammatory (M2) phenotype\n2. **Cytokine Reduction**: Decreases TNF-α, IL-1β, IL-6 production\n3. **NF-κB Inhibition**: Reduces pro-inflammatory signaling\n4. **T Cell Regulation**: Modulates CNS immune responses\n\n### Mitochondrial Protection\n\nApelin-13 promotes mitochondrial health:\n\n- **Biogenesis**: Increases PGC-1α expression and mitochondrial replication\n- **Fusion**: Enhances Mfn1/2 and OPA1-mediated fusion\n- **Mitophagy**: Facilitates PINK1/Parkin-independent mitophagy\n- **ATP Production**: Improves mitochondrial respiration\n\n### Neuronal Survival\n\nNeuroprotective signaling through:\n\n- **AKT Pathway**: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)\n- **ERK Pathway**: Activation promotes neuronal survival\n- **CREB Activation**: Enhances BDNF expression and synaptic plasticity\n- **Calcium Regulation**: Modulates calcium homeostasis\n\n## Role in Specific Diseases\n\n### Alzheimer's Disease\n\nApelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:\n\n### Parkinson's Disease\n\nApelin-13 shows neuroprotection in PD models[@yang2017]:\n\n- **Dopaminergic Protection**: Preserves tyrosine hydroxylase neurons\n- **Mitochondrial Rescue**: Improves complex I function\n- **Motor Improvement**: Reduces akinesia in MPTP models\n- **Alpha-Syn Clearance**: Autophagy enhancement\n\n### Amyotrophic Lateral Sclerosis\n\nIn ALS models, apelin shows[@jiang2018]:\n\n- **Motor Neuron Protection**: Reduces motor neuron loss\n- **Glial Modulation**: Affects astrocyte and microglial reactivity\n- **SOD1 Clearance**: Enhances mutant SOD1 removal\n- **Extended Survival**: Improves lifespan in transgenic models\n\n### CBS/PSP (4R-Tauopathies)\n\nApelin modulation may benefit 4R-tauopathies:\n\n- **Tau Clearance**: Autophagy enhancement aids tau removal\n- **BBB Protection**: Important for brainstem regions affected in PSP\n- **Neuroinflammation**: Reduces tau-induced inflammation\n\n## Therapeutic Approaches\n\n### Apelin Receptor Agonists\n\n### Apelin Peptide Analogs\n\nModified analogs under development:\n\n- **PEGylated apelin**: Extended half-life\n- **D-amino acid analogs**: Protease resistance\n- **Small peptide fragments**: Blood-brain barrier penetration\n\n### Clinical Trials\n\nCurrently limited clinical trial data for CNS applications:\n\n1. **(TBD)**: Apelin infusion in heart failure (not CNS)\n2. **(TBD)**: APJ agonist in pulmonary hypertension\n3. No registered trials for neurodegenerative indications\n\n### Challenges\n\n- **BBB Penetration**: Apelin peptides do not cross BBB efficiently\n- **Stability**: Rapid degradation by proteases\n- **Receptor Desensitization**: Chronic exposure reduces signaling\n- **Dose Timing**: Optimal window for intervention unclear\n\n### Delivery Strategies\n\n## Cross-References\n\n- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)\n- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)\n- [Corticobasal Syndrome](/diseases/corticobasal-degeneration)\n\n## See Also\n\n- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)\n- [Neuroprotective Strategies](/therapeutics/nfl-reduction-therapy)\n- [Peptide Therapeutics](/content/therapeutics)\n- [Gene Therapy Approaches](/therapeutics/section-113-emerging-gene-therapy-cbs-psp)\n- [Autophagy Modulators](/mechanisms/autophagy-lysosome-pathway)\n\n## External Links\n\n- [NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)\n- [UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)\n- [PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)\n\n## References\n\n1. [O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.\n\n2. [Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.\n\n3. [Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.\n\n4. [Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.\n\n5. [Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.\n\n6. [Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.\n\n7. [Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.\n\n8. [Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.\n\n9. [Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.\n\n10. [Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style=\"color:#ffd54f;font-weight:600\">0.44</span> · Target: TH, AADC\n- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style=\"color:#81c784;font-weight:600\">0.73</span> · Target: BDNF\n- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style=\"color:#81c784;font-weight:600\">0.71</span> · Target: GLP1R, BDNF\n- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style=\"color:#ffd54f;font-weight:600\">0.48</span> · Target: CHR2/BDNF\n- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: CYP46A1\n- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SST\n- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: HCRTR1/HCRTR2\n- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SMPD1\n\n\n**Related Analyses:**\n- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;\n- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;\n- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;\n",
  "entity_type": "therapeutic"
}

{
  "content_md": "# Apelin Receptor Modulation Therapy\n\n## Overview\n\n<table class=\"infobox infobox-therapeutic\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Apelin Receptor Modulation Therapy</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Peptide</td>\n    <td>Amino Acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-36</td>\n    <td>36</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-16</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-12</td>\n    <td>12</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Effect</td>\n    <td>Mechanism</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Amyloid Reduction</td>\n    <td>Enhanced autophagy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Tau Modification</td>\n    <td>GSK-3β inhibition</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Synaptic Protection</td>\n    <td>CREB/BDNF</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Cognitive Improvement</td>\n    <td>Multiple</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Compound</td>\n    <td>Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">\\[Pyr^1\\]-Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule Agonists</td>\n    <td>Small molecule</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV-APJ</td>\n    <td>Gene therapy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Strategy</td>\n    <td>Approach</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Intranasal</td>\n    <td>Direct to CNS</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV Vector</td>\n    <td>Gene delivery</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Exosomes</td>\n    <td>Cell-derived</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule</td>\n    <td>Oral delivery</td>\n  </tr>\n</table>\n\nApelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[@obrien2012][@cook2014].\n\nApelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.\n\n## The Apelin-APJ System\n\n### Apelin Peptides\n\nThe apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:\n\nApelin-13 and its stable analog \\[Pyr^1\\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.\n\n### APJ Receptor (APLNR)\n\nThe APJ receptor is a Class A GPCR that:\n\n- Couples to multiple G proteins (Gαi/o, Gαq)\n- Activates PI3K/AKT, MAPK/ERK, and AMPK pathways\n- Undergoes ligand-dependent and independent (constitutive) signaling\n- Dimerizes with other receptors (e.g., angiotensin AT1 receptor)\n\n## Mechanisms of Neuroprotection\n\n### Autophagy Enhancement\n\nApelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:\n\n1. **AMPK Activation**: Phosphorylates AMPK, enhancing TFEB nuclear translocation\n2. **mTOR Inhibition**: Reduces mTORC1 activity, relieving autophagy suppression\n3. **Autophagosome Formation**: Increases LC3-II conversion and autophagosome numbers\n4. **Lysosomal Function**: Enhances lysosomal biogenesis and function\n\nThis autophagy enhancement is particularly relevant for:\n\n- **Alzheimer's Disease**: Clearing amyloid-beta and tau aggregates\n- **Parkinson's Disease**: Removing alpha-synuclein aggregates\n- **ALS**: Degrading TDP-43 and SOD1 aggregates\n\n### Blood-Brain Barrier Protection\n\nApelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:\n\n- **Tight Junction Preservation**: Maintains claudin-5 and ZO-1 expression\n- **Endothelial Survival**: Promotes endothelial cell survival via AKT\n- **Reduced Permeability**: Decreases BBB leakage in injury models\n- **Angiogenesis Regulation**: Modulates new vessel formation\n\nBBB protection is critical for:\n\n- Limiting neurotoxin entry into the CNS\n- Maintaining CNS immune privilege\n- Ensuring proper drug delivery\n\n### Neuroinflammation Modulation\n\nApelin modulates neuroinflammation through[@chen2024]:\n\n1. **Microglial Polarization**: Shifts microglia toward anti-inflammatory (M2) phenotype\n2. **Cytokine Reduction**: Decreases TNF-α, IL-1β, IL-6 production\n3. **NF-κB Inhibition**: Reduces pro-inflammatory signaling\n4. **T Cell Regulation**: Modulates CNS immune responses\n\n### Mitochondrial Protection\n\nApelin-13 promotes mitochondrial health:\n\n- **Biogenesis**: Increases PGC-1α expression and mitochondrial replication\n- **Fusion**: Enhances Mfn1/2 and OPA1-mediated fusion\n- **Mitophagy**: Facilitates PINK1/Parkin-independent mitophagy\n- **ATP Production**: Improves mitochondrial respiration\n\n### Neuronal Survival\n\nNeuroprotective signaling through:\n\n- **AKT Pathway**: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)\n- **ERK Pathway**: Activation promotes neuronal survival\n- **CREB Activation**: Enhances BDNF expression and synaptic plasticity\n- **Calcium Regulation**: Modulates calcium homeostasis\n\n## Role in Specific Diseases\n\n### Alzheimer's Disease\n\nApelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:\n\n### Parkinson's Disease\n\nApelin-13 shows neuroprotection in PD models[@yang2017]:\n\n- **Dopaminergic Protection**: Preserves tyrosine hydroxylase neurons\n- **Mitochondrial Rescue**: Improves complex I function\n- **Motor Improvement**: Reduces akinesia in MPTP models\n- **Alpha-Syn Clearance**: Autophagy enhancement\n\n### Amyotrophic Lateral Sclerosis\n\nIn ALS models, apelin shows[@jiang2018]:\n\n- **Motor Neuron Protection**: Reduces motor neuron loss\n- **Glial Modulation**: Affects astrocyte and microglial reactivity\n- **SOD1 Clearance**: Enhances mutant SOD1 removal\n- **Extended Survival**: Improves lifespan in transgenic models\n\n### CBS/PSP (4R-Tauopathies)\n\nApelin modulation may benefit 4R-tauopathies:\n\n- **Tau Clearance**: Autophagy enhancement aids tau removal\n- **BBB Protection**: Important for brainstem regions affected in PSP\n- **Neuroinflammation**: Reduces tau-induced inflammation\n\n## Therapeutic Approaches\n\n### Apelin Receptor Agonists\n\n### Apelin Peptide Analogs\n\nModified analogs under development:\n\n- **PEGylated apelin**: Extended half-life\n- **D-amino acid analogs**: Protease resistance\n- **Small peptide fragments**: Blood-brain barrier penetration\n\n### Clinical Trials\n\nCurrently limited clinical trial data for CNS applications:\n\n1. **(TBD)**: Apelin infusion in heart failure (not CNS)\n2. **(TBD)**: APJ agonist in pulmonary hypertension\n3. No registered trials for neurodegenerative indications\n\n### Challenges\n\n- **BBB Penetration**: Apelin peptides do not cross BBB efficiently\n- **Stability**: Rapid degradation by proteases\n- **Receptor Desensitization**: Chronic exposure reduces signaling\n- **Dose Timing**: Optimal window for intervention unclear\n\n### Delivery Strategies\n\n## Cross-References\n\n- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)\n- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)\n- [Corticobasal Syndrome](/diseases/corticobasal-degeneration)\n\n## See Also\n\n- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)\n- [Neuroprotective Strategies](/therapeutics/nfl-reduction-therapy)\n- [Peptide Therapeutics](/content/therapeutics)\n- [Gene Therapy Approaches](/therapeutics/section-113-emerging-gene-therapy-cbs-psp)\n- [Autophagy Modulators](/mechanisms/autophagy-lysosome-pathway)\n\n## External Links\n\n- [NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)\n- [UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)\n- [PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)\n\n## References\n\n1. [O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.\n\n2. [Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.\n\n3. [Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.\n\n4. [Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.\n\n5. [Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.\n\n6. [Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.\n\n7. [Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.\n\n8. [Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.\n\n9. [Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.\n\n10. [Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style=\"color:#ffd54f;font-weight:600\">0.44</span> · Target: TH, AADC\n- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style=\"color:#81c784;font-weight:600\">0.73</span> · Target: BDNF\n- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style=\"color:#81c784;font-weight:600\">0.71</span> · Target: GLP1R, BDNF\n- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style=\"color:#ffd54f;font-weight:600\">0.48</span> · Target: CHR2/BDNF\n- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: CYP46A1\n- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SST\n- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: HCRTR1/HCRTR2\n- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SMPD1\n\n\n**Related Analyses:**\n- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;\n- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;\n- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;\n",
  "entity_type": "therapeutic"
}

{
  "content_md": "## Overview\n\n<table class=\"infobox infobox-therapeutic\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Apelin Receptor Modulation Therapy</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Peptide</td>\n    <td>Amino Acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-36</td>\n    <td>36</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-16</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-12</td>\n    <td>12</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Effect</td>\n    <td>Mechanism</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Amyloid Reduction</td>\n    <td>Enhanced autophagy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Tau Modification</td>\n    <td>GSK-3β inhibition</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Synaptic Protection</td>\n    <td>CREB/BDNF</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Cognitive Improvement</td>\n    <td>Multiple</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Compound</td>\n    <td>Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">\\[Pyr^1\\]-Apelin-13</td>\n    <td>Peptide</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule Agonists</td>\n    <td>Small molecule</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV-APJ</td>\n    <td>Gene therapy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Strategy</td>\n    <td>Approach</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Intranasal</td>\n    <td>Direct to CNS</td>\n  </tr>\n  <tr>\n    <td class=\"label\">AAV Vector</td>\n    <td>Gene delivery</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Exosomes</td>\n    <td>Cell-derived</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Small Molecule</td>\n    <td>Oral delivery</td>\n  </tr>\n</table>\n\nApelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[@obrien2012][@cook2014].\n\nApelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.\n\n## The Apelin-APJ System\n\n### Apelin Peptides\n\nThe apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:\n\nApelin-13 and its stable analog \\[Pyr^1\\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.\n\n### APJ Receptor (APLNR)\n\nThe APJ receptor is a Class A GPCR that:\n\n- Couples to multiple G proteins (Gαi/o, Gαq)\n- Activates PI3K/AKT, MAPK/ERK, and AMPK pathways\n- Undergoes ligand-dependent and independent (constitutive) signaling\n- Dimerizes with other receptors (e.g., angiotensin AT1 receptor)\n\n## Mechanisms of Neuroprotection\n\n### Autophagy Enhancement\n\nApelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:\n\n1. **AMPK Activation**: Phosphorylates AMPK, enhancing TFEB nuclear translocation\n2. **mTOR Inhibition**: Reduces mTORC1 activity, relieving autophagy suppression\n3. **Autophagosome Formation**: Increases LC3-II conversion and autophagosome numbers\n4. **Lysosomal Function**: Enhances lysosomal biogenesis and function\n\nThis autophagy enhancement is particularly relevant for:\n\n- **Alzheimer's Disease**: Clearing amyloid-beta and tau aggregates\n- **Parkinson's Disease**: Removing alpha-synuclein aggregates\n- **ALS**: Degrading TDP-43 and SOD1 aggregates\n\n### Blood-Brain Barrier Protection\n\nApelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:\n\n- **Tight Junction Preservation**: Maintains claudin-5 and ZO-1 expression\n- **Endothelial Survival**: Promotes endothelial cell survival via AKT\n- **Reduced Permeability**: Decreases BBB leakage in injury models\n- **Angiogenesis Regulation**: Modulates new vessel formation\n\nBBB protection is critical for:\n\n- Limiting neurotoxin entry into the CNS\n- Maintaining CNS immune privilege\n- Ensuring proper drug delivery\n\n### Neuroinflammation Modulation\n\nApelin modulates neuroinflammation through[@chen2024]:\n\n1. **Microglial Polarization**: Shifts microglia toward anti-inflammatory (M2) phenotype\n2. **Cytokine Reduction**: Decreases TNF-α, IL-1β, IL-6 production\n3. **NF-κB Inhibition**: Reduces pro-inflammatory signaling\n4. **T Cell Regulation**: Modulates CNS immune responses\n\n### Mitochondrial Protection\n\nApelin-13 promotes mitochondrial health:\n\n- **Biogenesis**: Increases PGC-1α expression and mitochondrial replication\n- **Fusion**: Enhances Mfn1/2 and OPA1-mediated fusion\n- **Mitophagy**: Facilitates PINK1/Parkin-independent mitophagy\n- **ATP Production**: Improves mitochondrial respiration\n\n### Neuronal Survival\n\nNeuroprotective signaling through:\n\n- **AKT Pathway**: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)\n- **ERK Pathway**: Activation promotes neuronal survival\n- **CREB Activation**: Enhances BDNF expression and synaptic plasticity\n- **Calcium Regulation**: Modulates calcium homeostasis\n\n## Role in Specific Diseases\n\n### Alzheimer's Disease\n\nApelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:\n\n### Parkinson's Disease\n\nApelin-13 shows neuroprotection in PD models[@yang2017]:\n\n- **Dopaminergic Protection**: Preserves tyrosine hydroxylase neurons\n- **Mitochondrial Rescue**: Improves complex I function\n- **Motor Improvement**: Reduces akinesia in MPTP models\n- **Alpha-Syn Clearance**: Autophagy enhancement\n\n### Amyotrophic Lateral Sclerosis\n\nIn ALS models, apelin shows[@jiang2018]:\n\n- **Motor Neuron Protection**: Reduces motor neuron loss\n- **Glial Modulation**: Affects astrocyte and microglial reactivity\n- **SOD1 Clearance**: Enhances mutant SOD1 removal\n- **Extended Survival**: Improves lifespan in transgenic models\n\n### CBS/PSP (4R-Tauopathies)\n\nApelin modulation may benefit 4R-tauopathies:\n\n- **Tau Clearance**: Autophagy enhancement aids tau removal\n- **BBB Protection**: Important for brainstem regions affected in PSP\n- **Neuroinflammation**: Reduces tau-induced inflammation\n\n## Therapeutic Approaches\n\n### Apelin Receptor Agonists\n\n### Apelin Peptide Analogs\n\nModified analogs under development:\n\n- **PEGylated apelin**: Extended half-life\n- **D-amino acid analogs**: Protease resistance\n- **Small peptide fragments**: Blood-brain barrier penetration\n\n### Clinical Trials\n\nCurrently limited clinical trial data for CNS applications:\n\n1. **(TBD)**: Apelin infusion in heart failure (not CNS)\n2. **(TBD)**: APJ agonist in pulmonary hypertension\n3. No registered trials for neurodegenerative indications\n\n### Challenges\n\n- **BBB Penetration**: Apelin peptides do not cross BBB efficiently\n- **Stability**: Rapid degradation by proteases\n- **Receptor Desensitization**: Chronic exposure reduces signaling\n- **Dose Timing**: Optimal window for intervention unclear\n\n### Delivery Strategies\n\n## Cross-References\n\n- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)\n- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)\n- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)\n- [Corticobasal Syndrome](/diseases/corticobasal-degeneration)\n\n## See Also\n\n- [Growth Factor Therapies](/therapeutics/growth-factor-therapies)\n- [Neuroprotective Strategies](/therapeutics/nfl-reduction-therapy)\n- [Peptide Therapeutics](/content/therapeutics)\n- [Gene Therapy Approaches](/therapeutics/section-113-emerging-gene-therapy-cbs-psp)\n- [Autophagy Modulators](/mechanisms/autophagy-lysosome-pathway)\n\n## External Links\n\n- [NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)\n- [UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)\n- [PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)\n\n## References\n\n1. [O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.\n\n2. [Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.\n\n3. [Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.\n\n4. [Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.\n\n5. [Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.\n\n6. [Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.\n\n7. [Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.\n\n8. [Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.\n\n9. [Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.\n\n10. [Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style=\"color:#ffd54f;font-weight:600\">0.44</span> · Target: TH, AADC\n- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style=\"color:#81c784;font-weight:600\">0.73</span> · Target: BDNF\n- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style=\"color:#81c784;font-weight:600\">0.71</span> · Target: GLP1R, BDNF\n- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style=\"color:#ffd54f;font-weight:600\">0.48</span> · Target: CHR2/BDNF\n- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: CYP46A1\n- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SST\n- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: HCRTR1/HCRTR2\n- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style=\"color:#81c784;font-weight:600\">0.77</span> · Target: SMPD1\n\n\n**Related Analyses:**\n- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;\n- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;\n- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;\n",
  "entity_type": "therapeutic"
}